Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ioforminol SCHEMBL374830 | 0.97 | LMNA (0.65) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL2763827 | 0.96 | LMNA (0.60) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL8583797 | 0.95 | CYP2C19 (0.60) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL8588233 | 0.94 | CYP2C19 (0.59) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL3783951 | 0.94 | LMNA (0.60) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL14478600 | 0.93 | LMNA (0.63) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL1742986 | 0.92 | LMNA (0.59) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL1742983 | 0.91 | LMNA (0.58) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL14329930 | 0.91 | LMNA (0.61) | CYP2C19HIF1ALMNAEGFRSRC | |
| SCHEMBL1742158 | 0.91 | LMNA (0.58) | CYP2C19HIF1ALMNAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0855997-A4 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA INC (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0855997-A1 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA, INC. (US) | 1998-08-05 | — | — | EP | claimed |
| WO-1997000240-A1 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA FOUNDATION (US) | 1997-01-03 | — | — | WO | claimed |
| US-20140322139-A1 | STABILIZATION OF X-RAY DIAGNOSTIC COMPOSITION | GE HEALTHCARE AS (NO) | 2014-10-30 | — | — | US | disclosed |
| US-20140322139-A1 | STABILIZATION OF X-RAY DIAGNOSTIC COMPOSITION | GE HEALTHCARE AS (NO) | 2014-10-30 | — | — | US | disclosed |
| WO-2013092783-A1 | STABILIZATION OF X-RAY DIAGNOSTIC COMPOSITION | GE HEALTHCARE AS (NO) | 2013-06-27 | — | — | WO | disclosed |
| EP-0855997-A4 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA INC (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0855997-A1 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA, INC. (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997000240-A1 | FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA | BIOPHYSICA FOUNDATION (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322139-A1 | STABILIZATION OF X-RAY DIAGNOSTIC COMPOSITION | SOST, SLCO1B1, IPO4 | CYP2C19 1138/4885HIF1A 3682/4885LMNA 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.